SUMMARY Eight monoclonal antibodies have been raised to antigenic determinants within the liver specific lipoprotein complex. Five of these determinants were species and the others non-species specific. No liver specific determinants were identified. Liver specific lipoprotein antigens recognised by the eight monoclonal antibodies were located either on the hepatocyte membrane and/or along the sinusoidal lining wall or in the cytoplasm of liver parenchymal cells. All antibodies but one reacted with the cell membrane of viable human hepatocytes. The molecular weights of four liver specific lipoprotein-determinants were determined by immunoprecipitation. These ranged from 22 000 to 164 000 daltons.
60 minutes. The supernatant was divided into 20 ml aliquots and stored at -20°C for up to eight months. A 20 ml aliquot of the supernatant was applied to a sepharose 6B (Pharmacia) column, gel bed 58x5 cm, and eluted with Tris-HCl buffer, pH 8-0 containing 0-2 M NaCl, 1 mM disodium-EDTA and 0-05% sodium azide. The void volume was concentrated using sucrose, and the protein content was measured according to Lowry .'0 The total yield from 10 ml of supernatant was 13-16 mg liver specific lipoprotein within the various preparations. Liver specific lipoprotein was stored at 4°C. IMMUNISATION Four Balb/c mice were immunised intraperitoneally with 50 ,ug liver specific lipoprotein in complete Freunds adjuvant at time 0, 4, and 8 weeks. Mouse 1 was given an intravenous booster injection of 10 ,ug liver specific lipoprotein immediately and mouse 2 a booster injection after a further three months. Mice 3 and 4 were boosted intraperitoneally with 25 ,ug liver specific lipoprotein and killed four weeks later after a final intravenous booster injection of 5-10 ,ug 510 liver specific lipoprotein. Spleens were harvested three to four days later from anitbody producing mice. Three different liver specific lipoprotein preparations were used for the immunisation procedure.
PRODUCTION OF HYBRID CELL LINES
Fusions were performed by a modification of the method described by Galfre et al. 11 Spleens of antibody producing animals were removed and mixed with myeloma cells (P3-NS1/1-Ag 4-1) in a ratio 10:1. The cell mixtures were pelleted at 200 g for five minutes and incubated with 1 ml polyethylene glycol 1500 (BDH Chemicals Ltd) (66.4% w/v) for seven minutes at 37°C. The fusion mixture was then gradually diluted by addition of small aliquots of RPMI 1640 (Flow). Finally the cells (1x 106 cells/ml) were dispensed in 2 ml linbro trays (Flow). Twenty four hours later 1 ml HAT medium (RPMI 1640 containing 10% FCS, 2 mM glutamine, 10-4 M hypoxanthine, 4x 10-7 M aminopterin, 1 6x 10-5 M thymidine and antibiotics) was added to each well. Beginning between day 10 to 14 the medium from wells showing cell growth was tested for antibody activity. Those hybridomas secreting specific antibody were cloned by limiting dilution (1 cell/well) in microtitre plates with feeder layers of normal spleen cells.
The monoclonal antibodies obtained from culture fluid in which the cells had been growing or from ascitic tumours in mice were purified by absorption onto a protein A-sepharose Cl-4B column (Pharmacia) eluting with pH 5.5 citrate buffer (0.1 mol/l citric acid, 01 mol/l disodium hydrogen phosphate).
DETERMINATION OF IMMUNOGLOBULIN CLASS OF MONOCLONAL ANTIBODIES
The immunoglobulin class of each monoclonal antibody was determined by double diffusion in 1 % agar gels (in Barbitone buffer pH 8 2) using immunoglobulin subclass specific antisera (Meloy).
BLOCKING EXPERIMENTS WITH MONOCLONAL ANTIBODIES
Monoclonal antibodies were used radiolabelled and unlabelled in blocking experiments to define their epitope specificity. Liver specific lipoprotein 0 5 ,ug and 100 000 cpm (100 ,ul) of radiolabelled antibody (incubation at 4°C for one hour) was found to be the optimum condition in this study. The blocking reagents were added in excess starting with 100 p.l of 2 mg/ml antibody and diluting them out to 1/1000. Washing procedures were carried out with phosphate buffered saline, pH 7 Figure 1 . Out of four separate fusion attempts 13 antibody producing hybridomas were selected by criteria of immunofluorescence reaction pattern on human liver tissue. When testing these antibodies by radiometric binding assay using four different liver specific lipoprotein preparations only eight of them reacted with liver specific lipoprotein (Fig. 2) . Further investigations concentrated on these antibodies (labelled RF-L1, 6, 8, 9, 10, 11, 12 and 13) . All were of IgGI clas s.
IMMUNOFLUORESCENCE PATTERNS OF ANTI-LIVER SPECIFIC LIPOPROTEIN MONOCLONAL ANTIBODIES ON LIVER SECTIONS AND ISOLATED HEPATOCYTES
The reaction pattern of the monoclonal antibodies on liver tissue sections and liver cell suspensions is described in Table 1 . Monoclonal antibody 1 showed a very weak binding to liver specific lipoprotein but displayed a clear membrane staining of hepatocytes (Fig. 3a) . Bile (Fig. 4) . The molecular weight range was from 164 K to 22K. The antigens precipitated by monoclonal antibodies 9 and 12 each displayed two bands in the autoradiograph. Various modifications of the technique -that is, using goat anti-mouse Ig coated S aureus and using detergents -did not lead to a successful precipitation of the proteins reacting with the remaining four antibodies. The existence of species specific and non-specific liver specific 1ipoprotein determinants has been reported earlierrand is supported by this study.
In contrast, the existence of a human liver specific determinant could not be shown in this study, confirming the work of other authors who failed to show liver specific antibodies when rabbits were immunised with liver specific lipoprotein. 18 20 The demonstration that liver specific lipoprotein contains numerous non-liver determinants raises problems when this antigen complex is used to analyse sera for liver-specific antibodies and peripheral blood lymphocytes for sensitisation to liver-specific antigens. These systems will detect sensitisation to non-liver specific determinants and the relevance of the reactions to liver injury is therefore difficult to establish. Immune responses to determinants, however, shared between the liver and other tissues may be the basis for the multisystemic distribution of lesions in patients with chronic hepatitis. For example, the demonstration of antigenic cross-reactivity of liver proteins with Tamm Horsfall proteins may explain the association of renal tubular acidosis with autoimmune chronic liver disease. 2' In this study, we have started to map the epitope display on the liver specific lipoprotein complex and have failed to confirm liver specificity. Whether any of these epitopes are the target of the autoantibodies responsible for liver damage has yet to be determined. Further identification of the epitope specificity of these autoantibodies using the techniques applied in this study is the first step in divising methods for regulation of this abnormal immune response by anti-idiotype or clonal deletion approaches. 
